

Nationwide survey of patients with primary immunodeficiency diseases in Japan

Ishimura, Masataka

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University

Takada, Hidetoshi

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University

Doi, Takehiko

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University

Imai, Kousuke

Department of Pediatrics, National Defense Medical College

他

<https://hdl.handle.net/2324/25680>

出版情報 : Journal of Clinical Immunology. 31 (6), pp.968-976, 2011-12-01. Springer Japan
バージョン :
権利関係 : (C) Springer Science+Business Media, LLC 2011

Title

Nation-wide survey of patients with primary immunodeficiency diseases in Japan

Authors

Masataka Ishimura¹⁾, Hidetoshi Takada¹⁾, Takehiko Doi¹⁾, Kousuke Imai²⁾, Yoji Sasahara³⁾, Hirokazu Kanegane⁴⁾, Ryuta Nishikomori⁵⁾, Tomohiro Morio⁶⁾, Toshio Heike⁵⁾, Masao Kobayashi⁷⁾, Tadashi Ariga⁸⁾, Shigeru Tsuchiya³⁾, Shigeaki Nonoyama²⁾, Toshio Miyawaki⁴⁾, and Toshiro Hara¹⁾

Affiliations

¹⁾ Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University

²⁾ Department of Pediatrics, National Defense Medical College

³⁾ Department of Pediatrics, Tohoku University School of Medicine

⁴⁾ Department of Pediatrics, Graduate School of Medicine and Pharmaceutical Science, University of Toyama

⁵⁾ Department of Pediatrics, Kyoto University Graduate School of Medicine

⁶⁾ Department of Pediatrics, Tokyo Medical and Dental University Graduate School

⁷⁾ Department of Pediatrics, Hiroshima University Graduate School of Biomedical Sciences

⁸⁾ Department of Pediatrics, Graduate School of Medicine, Hokkaido University

Corresponding author

Masataka Ishimura, MD. Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan; TEL: +81-92-642-5421, FAX: +81-92-642-5435, e-mail: ischii@pediatr.med.kyushu-u.ac.jp

Running Head

Epidemiological PID survey in Japan

Abbreviations

APECED; autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy, BTK; Bruton's tyrosine kinase, CGD; chronic granulomatous disease, CID; combined T and B cell immunodeficiency, CVID; common variable immunodeficiency disease, FMF; familial Mediterranean fever, IPEX; immune dysregulation polyendocrinopathy enteropathy X-linked, NEMO; nuclear factor kappa B essential modulator, PID; primary immunodeficiency disease, SIgAD; selective IgA deficiency, SLE; systemic lupus erythematosus, TRAPS; tumor necrosis factor receptor-associated periodic syndrome, WAS; Wiskott-Aldrich syndrome, WHIM; warts, hypogammaglobulinemia, infections, and myelokathexis

Introduction

Patients with primary immunodeficiency disease (PID) show susceptibility to infections due to congenital immune system defects. These patients are also associated with non-infectious complications, including autoimmune diseases and malignant disorders. Recent studies have revealed the causes of many PIDs to be mutations in various genes encoding molecules involved in the host defense mechanisms [1]. In addition, various new PIDs, including defects in innate immunity and autoinflammatory disorders, were identified under the recent progress in immunology and molecular genetics [2]. PID classification has been revised according to the identification of new PIDs and on the basis of new findings in PID pathophysiology. For a more precise clinical analysis, data should be obtained in accordance with the latest PID classifications.

The first nation-wide survey of patients with PID in Japan was conducted between 1974 and 1979, which included 497 registered cases [3]. By 2007, a total of 1,297 patients were cataloged by a small number of PID specialists into a registration system [4]. The approximate prevalence of PID patients in Japan in the first nation-wide survey was 1.0 in 100,000 people, which was much lower than that in other countries [5–7]. This difference in PID prevalence between Japan and other countries suggested that some PID patients in Japan remained unregistered. To determine the prevalence and clinical characteristics of patients

with PID in Japan on the basis of the recent international classification system for PID, we conducted a nation-wide survey of PID for the first time in 30 years.

Methods

This study was performed according to the nation-wide epidemiological survey manual of patients with intractable diseases (2nd edition 2006, Ministry of Health, Labour, and Welfare of Japan) as described previously [8]. PID classification was based on the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee in 2007 [2]. Patients with chronic benign neutropenia and syndrome of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis were excluded because these were considered to be acquired diseases. The survey was conducted on PID patients who were alive on December 1, 2008 and those who were newly diagnosed and dead between December 1, 2007 and November 30, 2008 in Japan. Among the 2291 pediatric departments and 8026 internal medicine departments in Japan, hospitals participating in the survey were randomly selected after setting the selection ratio according to the number of beds (overall selection rate: 53.4% for pediatric departments, 20.8% for internal medicine departments) (Table I). University hospitals and pediatric training hospitals, where many PID patients were considered to be treated, were stratified separately (Table I).

Primary questionnaires regarding the number of patients and disease names based on PID classification were sent to the selected hospitals. Secondary questionnaires regarding age, gender, clinical manifestations, and complications of individual PID patients were sent to respondents who answered that they observed at least one PID patient with characteristics listed in the primary questionnaires.

Results

Questionnaires were distributed to 1224 pediatric departments and 1670 internal medicine departments of hospitals in Japan, and the response rate was 55.0% and 20.1%, respectively (Table I). A total of 1,240 patients (1,146 patients from pediatric departments and 94 patients from internal medicine departments) were registered (Table I). The estimated number of patients with PIDs in Japan was 2,900 (95% confidence interval: 2,300–3,500) and the prevalence was 2.3 per 100,000 inhabitants. We also determined the regional distribution on the basis of the patients' addresses. The estimated regional prevalence ranged from 1.7 to 4.0 per 100,000 inhabitants, and no significant differences were observed between different regions in Japan (Fig. 1). The most common form of PID was predominantly antibody deficiencies (40%), followed by congenital defects of phagocyte number, function, or both (19%) and other well-defined

immunodeficiency syndromes (16%) (Table II). Autoinflammatory disorders were observed in 108 cases (9%). The most common PID was Bruton's tyrosine kinase (BTK) deficiency (182 cases, 14.7%), followed by chronic granulomatous disease (CGD) (147 cases, 11.9%). However, common variable immunodeficiency disease (CVID) and selective IgA deficiency (SIgAD) were observed only in 136 (11.0%) and 49 cases (4.0%), respectively. Among patients registered from internal medicine departments, antibody deficiencies were the most common disorder (71%).

In the secondary survey, 923 cases were registered. The male-to-female ratio was 2.3:1 ($n = 914$, unanswered: 9 cases) with a median age of 12.8 years (range: 0 to 75 years) ($n = 897$, unanswered: 26 cases). The number of adolescent or adult cases (≥ 15 years) was 384 (42.8%) (Fig. 2a). The male-to-female ratio of the younger generation (< 15 years) was 2.7:1, while that of the older generation (≥ 15 years) was 2.0:1. Combined T and B cell immunodeficiencies (CIDs) were predominantly observed in the younger generation, while antibody deficiencies were more common with increasing age (Fig. 2b). The median age of CID, BTK deficiency, CVID, and CGD patients was 5.2, 12.8, 25.1, and 14.7 years, respectively.

It is well known that PID patients are susceptible to many pathogens and experience community-acquired or opportunistic infections. In this study, we

focused on non-infectious complications of PID because they have been less well studied on a large scale and may provide important information for improving the quality of life of PID patients. Twenty-five PID cases developed malignant disorders (2.7%) (Table III). Lymphoma, in particular, Epstein-Barr virus-related, and leukemia were dominant, while there were no patients with gastric carcinoma. CVID, Wiskott-Aldrich syndrome (WAS), and ataxia telangiectasia were more frequently associated with malignant diseases among PID patients. A case of Mendelian susceptibility to mycobacterial disease with squamous cell carcinoma was also observed [9] (Table III).

Seventy-eight PID patients had immune-related (autoimmune) diseases (8.5%) (Table IVa). Autoimmune lymphoproliferative syndrome, immune dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome, and nuclear factor kappa B essential modulator (NEMO) deficiency were associated with immune-related diseases at a very high incidence. In addition, immune-related diseases were relatively common in CGD and CVID patients (Table IVa). The most commonly observed immune-related disease was inflammatory bowel disease (33 cases), which was most frequently observed in CGD patients, followed by immune thrombocytopenic purpura (13 cases), autoimmune hemolytic anemia (8 cases), and systemic lupus erythematosus (SLE) (8 cases) (Table IVa and b). Kawasaki disease occurred in WAS and CGD

patients. In addition, this is the first report of Kawasaki disease in patients with complement deficiency (C9) and familial Mediterranean fever (FMF). A patient with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome and a patient with tumor necrosis factor receptor-associated periodic syndrome (TRAPS) were first reported as cases of type 1 diabetes mellitus and SLE, respectively [10, 11].

Discussion

We conducted a nation-wide survey of PID for the first time in 30 years and report the prevalence of PID in Japan. We registered 1,240 PID patients and found that the estimated prevalence of PID (2.3/100,000) is higher than that previously reported (1.0/100,000) in Japan. Our results are equivalent to those reported in Singapore (2.7/100,000) and Taiwan (0.77–2.17/100,000) [12–14]. However, our values are lower than those reported in Middle Eastern countries such as Kuwait (11.98/100,000) or in European countries such as France (4.4/100,000) [5–7,15]. The high rate of consanguinity may be a cause of the high prevalence rate of PID reported in Middle Eastern countries [6, 15]. There may have been sample selection bias in this study because some asymptomatic cases (SIgAD, etc.), clinically recovered cases (transient hypogammaglobulinemia of infancy, etc.), and cases in which patients were deceased were not registered. In

addition, lack of recognition of PID in internal medicine departments, not just the low response rate, might also have influenced the estimated prevalence of PID as well as the age and disease distribution. The regional prevalence of PIDs in Japan was homogenous, unlike in other countries in which a higher prevalence was observed in urban areas [5, 7, 16]. This may be because many PID patients were treated or followed by PID specialists distributed nationwide in Japan; this is assumed by the location of hospitals with which they were affiliated.

The distribution ratios of BTK deficiency (14.7%) and CGD (11.9%) in Japan were higher than those in a previous report from Europe (5.87% and 4.33%, respectively), while those of CIDs and other well-defined immunodeficiency syndromes were comparable [17]. The prevalence of BTK deficiency was previously reported to be 1/900,000–1,400,000 in a European cohort study [18]. In contrast, this value was estimated to be 1/300,000 in Japan in our study. BTK deficiency appears to be common in Japan, although this may be partially because more patients, including those showing atypical clinical manifestations, were diagnosed more accurately by the recently established genetic diagnostic network in Japan [19]. This is supported by the highest proportion of Japanese patients in the international mutation database for X-linked agammaglobulinemia (BTKbase) [20]. The reason for the low number of registered CGD patients in Europe in a recent report (1/620,000) [17] is unknown;

the prevalence of CGD was 1 in 250,000 in a previous European survey [21], which was similar to our results (1 in 380,000 in this study and 1 in 280,000 in our previous study [22]). The percentage of BTK deficiency and CGD would be lower if more adult cases were registered because the prevalence of these disorders is low in adults. CVID was the most commonly reported PID (20.7%) in Europe, and the onset of symptoms was observed most commonly in the third decade of life in these patients [17, 23]. In this study, CVID constituted 11.0% (136 cases) of PID cases, and only 29 cases were reported from internal medicine departments (Table II). A lower number of registered CVID patients may have led to a lower number of reported patients with antibody deficiency and a lower prevalence of PID, although it is still possible that CVID is not as common in Japan as in European countries. There was no significant difference in the distribution rate of SIgAD between Japanese and Europeans, although SIgAD is rare in Japanese (1/18,500) compared with Caucasians (1/330–2,200) according to seroepidemiologic studies [24]. This may be because most SIgAD patients lack clinical manifestations. The distribution ratio of autoinflammatory disorders in Japan (9%) was much higher than that in Europe (1.02%) [17] (Table II). Considering the disease type of the autoinflammatory disorders was not specified in 22 cases (20%), it is possible that many other patients with autoinflammatory disorders remain undiagnosed in Japan as well as in other countries.

The percentage of men (69.7%) with PID is higher in Japan than in Europe (60.8%) or Kuwait (61.8%), but is equivalent to that in Taiwan (70.2%) [6, 13, 17]. The higher ratio of men, particularly in younger generation (<15 years), appears to be due to the larger number of X-linked PID patients (BTK deficiency, X-CGD, γ c deficiency, etc.) in this study compared to that in Europe or Kuwait. Adolescents or adults (≥ 15 years) constituted 42.8% of the patients in this study, which is equivalent to the number in the European study (≥ 16 years: 46.6%), while those >16 years constituted only 10.9% in the previous survey [3, 17]. In this study, it was found that CVID and SIgAD are common in adults (Table II) and antibody deficiencies are more common with increasing age (Fig. 2b). A reason for the increased number of adult PID patients may be long-term survival of PID patients due to improved treatments such as immunoglobulin replacement therapy. In addition, an increased likelihood of patients being diagnosed by internists as having late-onset PID, e.g., CVID and SIgAD, may have contributed to these values [17, 25, 26]. Therefore, it is important for internists to be well-informed regarding PID. In contrast, CIDs are fatal during infancy without hematopoietic stem cell transplantation or gene therapy. Because hematopoietic stem cell transplantation has been widely performed in Japan since the 1990s, surviving patients with CID are limited to the younger generation, similar to French patients (Fig. 2b) [5, 27, 28].

It has been reported that PID patients are at increased risk of developing malignant diseases, in particular, non-Hodgkin lymphoma, leukemia, and stomach cancer [29]. Although lymphoma and leukemia were relatively common, stomach cancer was not observed in our study. In the previous survey in Japan, eight of nine PID patients with malignant disorders (including one gastric cancer patient) died [3]. It is possible that some PID patients with malignant disorders were not registered because they were deceased. PID is also associated with immune-related diseases because of a defect in the mechanisms to control self-reactive B and T cells. The frequency of immune-related manifestations varied among individual PID patients, as reported previously [30, 31]. Four PID patients who had developed Kawasaki disease, one patient with WHIM syndrome and type 1 diabetes mellitus, and one patient with TRAPS and SLE in our study may provide new pathophysiological insights of these diseases and the association between PID and autoimmune diseases.

Conclusions

We report the prevalence and clinical characteristics of PIDs in Japan. Although the advances in diagnostic technologies and treatments have improved the prognoses of PID, many patients continue to experience severe complications such as malignancy and immune-related diseases as well as infections. To

improve the quality of life of PID patients, it is necessary to pay attention to complications and treat them appropriately. Web-based PID databases and consultation systems have been created in Japan (Primary Immunodeficiency Database in Japan [4] and Resource of Asian Primary Immunodeficiency Diseases in Asian countries [32]) to reveal precise information regarding PID and to promote cooperation between doctors and researchers [19].

Acknowledgments

This study was supported by the Japanese Research Group on Primary Immunodeficiency Diseases, supported by the Ministry of Health, Labour and Welfare in Japan.

References

1. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182-94.
2. Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, et al. Primary immunodeficiency diseases: An update from the international union of immunological societies primary immunodeficiency diseases classification committee. J Allergy Clin Immunol. 2007;120(4):776-94.
3. Hayakawa H, Iwata T, Yata J, Kobayashi N. Primary immunodeficiency syndrome in Japan. I. overview of a nationwide survey on primary immunodeficiency syndrome. J Clin Immunol. 1981;1(1):31-9.
4. Primary Immunodeficiency Database in Japan (PIDJ): <http://pidj.rcai.riken.jp/>
(in Japanese)
5. CEREDIH: The French PID study group: The French national registry of primary immunodeficiency diseases. Clin Immunol. 2010;135(2):264-72.

6. Al-Herz W. Primary immunodeficiency disorders in Kuwait: First report from Kuwait national primary immunodeficiency registry (2004--2006). *J Clin Immunol.* 2008;28(2):186-93.
7. Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary immunodeficiency diseases in Norway. *J Clin Immunol.* 2000;20(6):477-85.
8. Nakamura Y, Matsumoto T, Tamakoshi A, Kawamura T, Seino Y, Kasuga M, et al. Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. *J Epidemiol.* 2000;10(1):29-33.
9. Toyoda H, Ido M, Nakanishi K, Nakano T, Kamiya H, Matsumine A, et al. Multiple cutaneous squamous cell carcinomas in a patient with interferon gamma receptor 2 (IFN gamma R2) deficiency. *J Med Genet.* 2010;47(9):631-4.
10. Takaya J, Fujii Y, Higashino H, Taniuchi S, Nakamura M, Kaneko K. A case of WHIM syndrome associated with diabetes and hypothyroidism. *Pediatr Diabetes.* 2009;10(7):484-6.
11. Ida H, Kawasaki E, Miyashita T, Tanaka F, Kamachi M, Izumi Y, et al. A novel

mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. *Rheumatology (Oxford)*. 2004;43(10):1292-9.

12. Lim DL, Thong BY, Ho SY, Shek LP, Lou J, Leong KP, et al. Primary immunodeficiency diseases in Singapore--the last 11 years. *Singapore Med J*. 2003;44(11):579-86.

13. Lee WI, Kuo ML, Huang JL, Lin SJ, Wu CJ. Distribution and clinical aspects of primary immunodeficiencies in a Taiwan pediatric tertiary hospital during a 20-year period. *J Clin Immunol*. 2005;25(2):162-73.

14. Lee WI, Huang JL, Jaing TH, Shyur SD, Yang KD, Chien YH, et al. Distribution, clinical features and treatment in Taiwanese patients with symptomatic primary immunodeficiency diseases (PIDs) in a nationwide population-based study during 1985-2010. *Immunobiology*. 2011 Jun 21 [Epub ahead of print]

15. Shabestari MS, Maljaei SH, Baradaran R, Barzegar M, Hashemi F, Mesri A,

et al. Distribution of primary immunodeficiency diseases in the Turk ethnic group, living in the northwestern Iran. *J Clin Immunol.* 2007;27(5):510-6.

16. Matamoros Flori N, Mila Llambi J, Espanol Boren T, Raga Borja S, Fontan Casariego G. Primary immunodeficiency syndrome in Spain: First report of the national registry in children and adults. *J Clin Immunol.* 1997;17(4):333-9.

17. Gathmann B, Grimbacher B, Beaute J, Dudoit Y, Mahlaoui N, Fischer A, et al. The European internet-based patient and research database for primary immunodeficiencies: Results 2006-2008. *Clin Exp Immunol.* 2009;157 Suppl 1:3-11.

18. Toth B, Volokha A, Mihas A, Pac M, Bernatowska E, Kondratenko I, et al. Genetic and demographic features of X-linked agammaglobulinemia in eastern and central Europe: A cohort study. *Mol Immunol.* 2009;46(10):2140-6.

19. Burrows PD, Fischer A. Building networks for immunodeficiency diseases and immunology training. *Nat Immunol.* 2008;9(9):1005-7.

20. Valiaho J, Smith CI, Vihinen M. BTKbase: The mutation database for

X-linked agammaglobulinemia. *Hum Mutat.* 2006;27(12):1209-17.

21. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: The European experience. *PLoS One.* 2009;4(4):e5234.

22. Hasui M. Chronic granulomatous disease in Japan: Incidence and natural history. the study group of phagocyte disorders of Japan. *Pediatr Int.* 1999;41(5):589-93.

23. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: Division into distinct clinical phenotypes. *Blood.* 2008;112(2):277-86.

24. Kanoh T, Mizumoto T, Yasuda N, Koya M, Ohno Y, Uchino H, et al. Selective IgA deficiency in Japanese blood donors: Frequency and statistical analysis. *Vox Sang.* 1986;50(2):81-6.

25. Aghamohammadi A, Moin M, Farhoudi A, Rezaei N, Pourpak Z, Movahedi M, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in

patients with agammaglobulinemia. *FEMS Immunol Med Microbiol.*

2004;40(2):113-8.

26. Quartier P, Debre M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, et al.

Early and prolonged intravenous immunoglobulin replacement therapy in

childhood agammaglobulinemia: A retrospective survey of 31 patients. *J Pediatr.*

1999;134(5):589-96.

27. Sakata N, Kawa K, Kato K, Yabe H, Yabe M, Nagasawa M, et al. Unrelated

donor marrow transplantation for congenital immunodeficiency and metabolic

disease: An update of the experience of the Japan marrow donor program. *Int J*

Hematol. 2004;80(2):174-82.

28. Morio T, Atsuta Y, Tomizawa D, Nagamura-Inoue T, Kato K, Ariga T, et al.

Outcome of unrelated umbilical cord blood transplantation in 88 patients with

primary immunodeficiency in Japan. *Br J Haematol.* 2011;154(3):363-72.

29. Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton S.

Are antibody deficiency disorders associated with a narrower range of cancers

than other forms of immunodeficiency? *Blood.* 2010;116(8):1228-34.

30. Bussone G, Mouthon L. Autoimmune manifestations in primary immune deficiencies. *Autoimmun Rev.* 2009;8(4):332-6.
31. Arason GJ, Jorgensen GH, Ludviksson BR. Primary immunodeficiency and autoimmunity: Lessons from human diseases. *Scand J Immunol.* 2010;71(5):317-28.
32. Resource of Asian Primary Immunodeficiency Diseases (RAPID):
<http://rapid.rcai.riken.jp/RAPID/>